ReviewJournal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi2022
COVID-19 associated mucormycosis - An emerging threat.
Review in Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Mucorales: A systematic review to inform the World Health Organization priority list of fungal pathogens.Medical mycology · 2024Pooled it
- COVID-19-associated mucormycosis: a systematic review and meta-analysis of 958 cases.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2023Pooled it
- Inflammatory indices as early predictors of mortality in mucormycosis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Association Between Sodium-Glucose Cotransporter-2 Inhibitors and Sepsis Risk in Patients With Type 2 Diabetes Mellitus.Journal of diabetes research · 2026Article
- Comparative Mortality and Risk Analysis in Mucormycosis Cases: Pre-Pandemic Versus COVID-19 Association.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2025Article
- Direct Targeted Degradation of Transposon RNAs by the Non-Canonical RNAi Pathway of the FungusInternational journal of molecular sciences · 2025Article
- Molecular insights into the bidirectional link between anxiety and COVID-19: a combined clinical and bioinformatics approach.Frontiers in psychiatry · 2025Article
- Risk Factors of COVID-19 associated mucormycosis in Iranian patients: a multicenter study.BMC infectious diseases · 2024Observational
- COVID-19-Associated Rhinocerebral Mucormycosis, an Incidental Finding or a Matter of Concern - Mixed-Method Systematic Review.Infection and drug resistance · 2024Review
- Causal associations and genetic overlap between COVID-19 and intelligence.QJM : monthly journal of the Association of Physicians · 2023Article
- COVID-19 associated Mucormycosis among ICU patients: risk factors, control, and challenges.AMB Express · 2023Review
- Antifungal Development and the Urgency of Minimizing the Impact of Fungal Diseases on Public Health.ACS bio & med chem Au · 2023Review
- Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment.Journal of medical virology · 2023Review
- Editorial: The World Health Organization (WHO) Fungal Priority Pathogens List in Response to Emerging Fungal Pathogens During the COVID-19 Pandemic.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- COVID-19 Associated with Cryptococcosis: A New Challenge during the Pandemic.Journal of fungi (Basel, Switzerland) · 2022Review
- Immunohistochemical expression of angiotensin-converting enzyme 2 in superficial and deep maxillofacial tissues: A cross-sectional study.Health science reports · 2022Article
- Mucormycosis and COVID-19-Associated Mucormycosis: Insights of a Deadly but Neglected Mycosis.Journal of fungi (Basel, Switzerland) · 2022Review
- Changing Epidemiology of Respiratory Tract Infection during COVID-19 Pandemic.Antibiotics (Basel, Switzerland) · 2022Review
- Fungal Colonization and Infections-Interactions with Other Human Diseases.Pathogens (Basel, Switzerland) · 2022Review
- Overview of COVID-19-Associated Invasive Fungal Infection.Current fungal infection reports · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly become a global threaten since its emergence in the end of 2019. Moreover, SARS-CoV-2 infection could also present with co-infection or secondary infection by other virus, bacteria, or fungi. Among them, mucormycosis is a rare but aggressive fungal disease and it mainly affects patients particularly with poorly controlled diabetes mellitus with diabetic ketoacidosis (DKA). We here did a comprehensive review of literature reporting COVID-19 associated with mucormycosis (CAM) cases, which have been reported worldwide. The prevalence is higher in India, Iran, and Egypt than other countries, particularly highest in the states of Gujarat and Maharashtra in India. Poor diabetic control and the administration of systemic corticosteroids are the common precipitating factors causing mucormycosis in the severe and critical COVID-19 patients. In addition, COVID-19 itself may affect the immune system resulting in vulnerability of the patients to mucormycosis. Appropriate treatments of CAM include strict glycemic control, extensive surgical debridement, and antifungal therapy with amphotericin B formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.